NCT02461849: Patients With Refractory, Metastatic Cancer Harboring KIT Mutation or Amplification to Investigate the Clinical Efficacy and Safety of Imatinib Therapy

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: KIT
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult), Senior)
Location of Metastases: 
Additional Notes: Patients must have a tumor that expresses KIT
Exclusions: Patients with active CNS metastases not controllable with radiotherapy or corticosteroids

Comments are closed.

Up ↑